There are substantial rural-urban disparities in cardiometabolic risk factors and cardiovascular diseases among US adults.

Maternal obesity had a strong influence on offspring obesity/severe obesity, and maternal smoking had a significant effect on all 3 outcomes.

Pfizer has made the decision to discontinue the clinical development program for danuglipron, an oral GLP-1 receptor agonist, being investigated for chronic weight management.

A scientific statement regarding the diagnosis and management of blood culture-negative endocarditis has been published by the AHA.

Physician burnout and intentions to reduce clinical effort or leave one’s institution are results of poor control over specific aspects of work.

A scientific statement regarding direct-to-consumer genetic testing for cardiovascular disease has been published by the AHA.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

There may be lower risk for HF among patients with low-to-moderate total alcohol consumption, except in women who drink beer, who may have higher risk.

Patients with infection-related hospitalization may have increased risk for incident heart failure, including HFrEF and HFpEF.

From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with T1D, and GLP-1 RA prescriptions also increased.

Federal cuts to funding could “decimate” medical research in the US, delaying cures and costing countless lives.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.